Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of stock-based compensation related to all of the entity's share-based payments

Total stock-based compensation related to all of our share-based payments that we recognized for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
Selling, general and administrative	$	1,352	$	1,611	$	3,981	$	5,519
Research and development		532		487		1,684		2,185
Total stock-based compensation expense	$	1,884	$	2,098	$	5,665	$	7,704

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
Risk-free interest rate	0.5	%	1.7	%	1.2	%	2.5	%
Expected term (in years)	6.7		6.0		6.5		6.5
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	70.5	%	63.0	%	66.0	%	65.6	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Nine Months Ended
	September 30,
	2020		2019
Risk-free interest rate	1.0	%	2.8	%
Expected term (in years)	1.6		1.7
Dividend yield	0.0	%	0.0	%
Expected volatility	62.3	%	63.0	%